Navigation Links
Nuvilex Advances Release of Citroxin(TM) Antiviral Surface Cleaner to Help Combat Swine Flu

CHERRY HILL, N.J., April 29 /PRNewswire-FirstCall/ --Nuvilex, Inc. (OTC Bulletin Board: NVLX), an emerging healthcare consumer products company, today announced that it will advance the release of Citroxin to domestic and international health agencies including hospitals, clinics, and medical offices as well as other at risk institutions and companies, such as schools and airlines. Nuvilex has proof of Citroxin's effectiveness in eliminating swine influenza virus (SIV; H1N1 subtype) and avian influenza virus (AIV; H9N9 subtype) on surface areas but has not yet submitted Citroxin for EPA approval as an antiviral agent. Citroxin samples will be provided at no cost and the Company will provide technical assistance. Citroxin is being released early as the current Swine Flu outbreak requires the best products be deployed to combat the growing epidemic.

Independent laboratory testing of Citroxin showed a 100% kill rate for the "big six" bacterial health threats, including E. coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, Streptococcus, and Black Mold. Citroxin is an EPA registered germicidal composition (EPA registration number 82723-1) and is patented in the US and world wide (US 7,439,218 and WIPO 2007/038265 A3).

Interested parties should contact A. Peter Morello III, Ph.D., Director of Research at Nuvilex via a specially set up email address: for product information and specifications as well as to request a sample.

"Given the seriousness of the threat of the spread of swine flu, we believe it is our duty to push hard to make Citroxin available as soon as possible," said Martin E. Schmieg, Chairman and CEO of Nuvilex, Inc. "Much of the innovation in science and technology for combating big problems comes from small companies such as Nuvilex. Moving our discoveries into the world takes resources - investment capital, which has all but disappeared from the market because of the current economic downturn. If Citroxin takes root as envisioned, demand will outpace our manufacturing capabilities and it will be necessary for us to seek a commercial partner to move the product quickly into the marketplace."

Citroxin is a eco-friendly surface cleaner. The Company's viral testing to date has been led by Sagar M. Goyal, D.V.M., Ph.D. at the University of Minnesota. Dr. Goyal has investigated the use of Citroxin to treat viral subtypes of SIV (H1N1). In Dr. Goyal's first experiment, his team evaluated the ability of Citroxin (dilutions of 1:10 and 1:100) to inhibit the replication of SIV H1N1 in vitro. Compared to the controls, high concentrations of Citroxin (1:10 dilution) were found to be virucidal for SIV growing in MDCK (Madin-Darby canine kidney) cells.

The Company, in conjunction with international based academic researchers, has also treated H9N9 AIV with Citroxin. In the AIV H9N9 experiments, Citroxin also served as a better virucidal agent when it received a smaller viral challenge (1000, 100, and 10 tissue culture infectious dose50, or TCID50, of virus).

"Although Citroxin is not yet proven to be immunogenic, experiments do suggest that Citroxin can serve as an effective cleaner or disinfectant for surfaces that may have come into contact with SIV, AIV, or other types of virus particles," said Dr. Morello. "We are ready, willing and able to help the global public health community in combating the swine flu outbreak."

About Nuvilex, Inc.

Nuvilex, formerly, Inc. is an emerging healthcare consumer products company with a portfolio of aesthetics, dermatology, environmental and nutraceutical products. The company's focus is on developing, licensing and commercializing healthcare products that address the health needs of consumers worldwide. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc., a diversified skin products technology company serving the fast-growing body art, aesthetic, cosmetic and skin therapy markets. More information is available at: or

Safe Harbor Statement

Statements contained in this presentation that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Forward-looking statements are sometimes identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and involve a number of risks and uncertainties that could cause the Company's actual results to differ materially from projected results. All parties are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, the planned share exchange with Freedom2 Holdings, Inc., our ability to secure additional financing, and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.

    Investor Relations Contacts:
    Blair Barnes
    Senior Vice President and Chief Financial Officer
    Nuvilex, Inc.
    Ph: 856-433-6088

    Amy Glynn
    The Ruth Group
    Ph: 646-536-7023

    Press Contact:
    Pat Arcand
    Arcand & Madison Public Relations
    Ph: 617-576-7777

SOURCE Nuvilex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nuvilex, Inc. Announces Investor Conference Call and Open House
2. Nuvilex, Inc.s Marketing Partner, CK41 to Launch purEffect(TM) in May
3. Nuvilex, Inc. Announces New Pricing for Cinnergen and Launch of dLife Advertising and Promotion Campaign
4. Nuvilex Provides Conference Call Replay Information
5. Nuvilex, Inc. Launches Spring Break Initiatives Designed to Raise Visibility Among Key Demographic Group
6. Nuvilex Infinitink Tattoo Ink Featured on PBS 26:46 TV Program
7., Inc. Changes Name to Nuvilex, Inc., Reflecting New Strategic Direction of Company
8. New advances in cancer research to be highlighted at University of Leicester
9. Male Cosmetic Surgery Slows Down While Female Cosmetic Surgery Advances
10. Survey Results: Health Care Technology Advances as Physician Frustration Grows
11. Stemedica Advances its Certification to Become a Licensed Manufacturer of Adult Stem Cells for U.S. Based Clinical Trials
Post Your Comments:
(Date:6/27/2016)... ... 27, 2016 , ... "FCPX editors can now reveal their media with growing ... said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings ... users can now reveal the media of their split screens with growing colorful panels. ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in ... ways they remain in the eye of the beholder, according to experts who offered ... The American Journal of Managed Care. For the full issue, click here . ...
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... 23, 2016 , , , ... 7, 2016 , , , , LOCATION: , , , ... , , , EXPERT PANELISTS:  , , , Frost & Sullivan,s ... Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program ... global pharmaceutical industry is witnessing an exceptional era. Several new demand ...
Breaking Medicine Technology: